GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

If you're too busy to keep monitoring your stock portfolio every other day, then investing in stocks that won't cause you a ...

Comedian Nikki Glaser, host of the 2025 Golden Globe Awards ceremony, dove right in at the start of her opening monologue: ...

Novo Nordisk has also filed for a label expansion in the US, and a decision is expected in the first half of 2025.

Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss drug Ozempic to include the reduction of kidney disease risk.

(RTTNews) - Novo Nordisk A/S (NVO), Thursday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has supported label update for weight-loss drug ...

Given Novo Nordisk's long-term prospects ... and it's pursuing several other label expansions. Eli Lilly can also count on many years of sales growth from its diabetes medicine Mounjaro (a ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Brown-Forman's stock is a compelling investment with stable revenue and profit margins. Learn why BF.B is a Buy.

Novo Nordisk said the European Union’s drug regulator supports a label expansion of its Ozempic diabetes drug to reflect its potential to lower the risk of conditions related to kidney disease ...

Ms. Gantt is now missing her colon and has an ileostomy bag attached to her abdomen. Now, she is suing Novo Nordisk, claiming that the drug's labels do not warn of all serious side effects, including ...